Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of SHR2285 in Healthy Caucasian Participants
NCT04829305Phase 1Completed
- Sponsor
- Atridia Pty Ltd
- Start
- May 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of shr2285 in thrombosis (3 arms), sponsored by Atridia Pty Ltd. Primary endpoint: Adverse events at 7 days. Started May 2021; status: completed.
02
Drugs
shr2285
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT04829305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04829305.